Source:http://linkedlifedata.com/resource/pubmed/id/11170947
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2001-2-22
|
pubmed:abstractText |
A randomized, double-blind, multicenter study was conducted to investigate the boosting effect of Vaqta or Havrix in 537 healthy adults 18-53 years of age who had received a single dose of Havrix either 24 or 52 weeks earlier. Subjects were randomized in a 2 : 1 ratio to receive either Vaqta or Havrix for their second dose of vaccine and followed for clinical reactions for 14 days after dose 2 was administered. Serum samples were collected immediately before dose 2 was administered and again 4 weeks later and evaluated for hepatitis A antibody (modified hepatitis A virus antibody assay). The booster response rate after administration of the second dose of either vaccine was similar (86.1% for Vaqta vs. 80.1% for Havrix). The geometric mean titers were also similar: 3274 mIU/mL (95% confidence interval [CI], 2776-3858) for Vaqta versus 2423 mIU/mL (95% CI, 1911-3074) for Havrix. The proportion of subjects who reported > or =1 injection-site adverse experiences was lower in the patients receiving Vaqta than in those receiving Havrix (36.6% vs. 59.7%; P<.001). The results of this study indicate that a regimen of Havrix followed by Vaqta is generally well tolerated and highly immunogenic.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1058-4838
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
32
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
396-401
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11170947-Adolescent,
pubmed-meshheading:11170947-Adult,
pubmed-meshheading:11170947-Aged,
pubmed-meshheading:11170947-Aged, 80 and over,
pubmed-meshheading:11170947-Double-Blind Method,
pubmed-meshheading:11170947-Female,
pubmed-meshheading:11170947-Hepatitis A,
pubmed-meshheading:11170947-Hepatitis A Antibodies,
pubmed-meshheading:11170947-Hepatitis A Vaccines,
pubmed-meshheading:11170947-Hepatitis Antibodies,
pubmed-meshheading:11170947-Hepatovirus,
pubmed-meshheading:11170947-Humans,
pubmed-meshheading:11170947-Immunization, Secondary,
pubmed-meshheading:11170947-Male,
pubmed-meshheading:11170947-Middle Aged,
pubmed-meshheading:11170947-Time Factors,
pubmed-meshheading:11170947-Vaccines, Inactivated
|
pubmed:year |
2001
|
pubmed:articleTitle |
Randomized, double-blind study in healthy adults to assess the boosting effect of Vaqta or Havrix after a single dose of Havrix.
|
pubmed:affiliation |
Weill Medical College of Cornell University, New York, NY, USA. bconnor@pol.net
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study
|